Lonza Group AG (SWX:LONN)
Switzerland · Delayed Price · Currency is CHF 569.80
-0.20 (-0.04%)
Jul 18, 2025, 5:36 PM CET
Revenue by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
Biologics | 3.68B | Log In | Log In | Log In | Log In | Upgrade |
Biologics Growth | 23.81% | Log In | Log In | Log In | Log In | Upgrade |
Small Molecules | 983.00M | Log In | Log In | Log In | Log In | Upgrade |
Small Molecules Growth | 18.79% | Log In | Log In | Log In | Log In | Upgrade |
Cell & Gene | 689.00M | Log In | Log In | Log In | Log In | Upgrade |
Cell & Gene Growth | 6.95% | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients | 1.05B | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients Growth | -10.32% | Log In | Log In | Log In | Log In | Upgrade |
Corporate | 172.00M | Log In | Log In | Log In | Log In | Upgrade |
Corporate Growth | 33.77% | Log In | Log In | Log In | Log In | Upgrade |
EBITDA by Product
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
Biologics Core EBITDA | 1.27B | Log In | Log In | Log In | Log In | Upgrade |
Biologics Core EBITDA Growth | 16.99% | Log In | Log In | Log In | Log In | Upgrade |
Small Molecules Core EBITDA | 351.00M | Log In | Log In | Log In | Log In | Upgrade |
Small Molecules Core EBITDA Growth | 38.66% | Log In | Log In | Log In | Log In | Upgrade |
Cell & Gene Core EBITDA | 108.00M | Log In | Log In | Log In | Log In | Upgrade |
Cell & Gene Core EBITDA Growth | -20.72% | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients Core EBITDA | 256.00M | Log In | Log In | Log In | Log In | Upgrade |
Capsules & Health Ingredients Core EBITDA Growth | -29.33% | Log In | Log In | Log In | Log In | Upgrade |
Corporate Core EBITDA | -73.00M | Log In | Log In | Log In | Log In | Upgrade |
Corporate Core EBITDA Growth | 26.56% | Log In | Log In | Log In | Log In | Upgrade |
Revenue by Geography
Fiscal year is January - December.
Year Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | NaN - NaN |
|---|---|---|---|---|---|---|
Europe | 3.14B | Log In | Log In | Log In | Log In | Upgrade |
Europe Growth | - | Log In | Log In | Log In | Log In | Upgrade |
North and Central America | 2.44B | Log In | Log In | Log In | Log In | Upgrade |
North and Central America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Latin America | 129.00M | Log In | Log In | Log In | Log In | Upgrade |
Latin America Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Asia | 837.00M | Log In | Log In | Log In | Log In | Upgrade |
Asia Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Australia & New Zealand | 17.00M | Log In | Log In | Log In | Log In | Upgrade |
Australia & New Zealand Growth | - | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic | 3.00M | Log In | Log In | Log In | Log In | Upgrade |
Other Geographic Growth | - | Log In | Log In | Log In | Log In | Upgrade |